Eli Lilly and Company $LLY Shares Purchased by Abacus Wealth Partners LLC

Key Points

• Abacus Wealth Partners LLC sharply increased its stake in Eli Lilly by 572% in the fourth quarter, ending with 2,708 shares worth about $2.91 million.
• Eli Lilly continues to draw bullish attention from analysts and investors after strong results, including an earnings beat and higher price targets from firms like Guggenheim and TD Cowen.
• The company remains a market favorite thanks to its dominant obesity/GLP-1 franchise and an expanding pipeline in areas such as ALS, GI disease, and immuno-dermatology.

Abacus Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 572.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,708 shares of the company's stock after buying an additional 2,305 shares during the quarter. Eli Lilly and Company accounts for about 0.3% of Abacus Wealth Partners LLC's holdings, making the stock its 29th biggest holding. Abacus Wealth Partners LLC's holdings in Eli Lilly and Company were worth $2,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares during the period. 10Elms LLP boosted its stake in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after buying an additional 24 shares during the period. Finally, Miller Global Investments LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for Eli Lilly, lifting its forecast to $36.30 per share from $36.06 and above the broader consensus of $35.80, signaling continued earnings momentum.
• Positive Sentiment: Guggenheim recently boosted Lilly’s price target by $52 after the company’s strong first-quarter results, reinforcing the view that analysts see more upside after another blowout quarter.
• Positive Sentiment: Media coverage continues to highlight Lilly as one of the most watched stocks, with commentary pointing to its dominant position in the weight-loss drug market and ongoing bullish investor interest. Article: Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Positive Sentiment: Several reports pointed to Lilly’s expanding pipeline, including new and advancing trials in ALS, GI disease, and immuno-dermatology, which adds optionality beyond its core diabetes and obesity franchises.
• Positive Sentiment: Investor sentiment also got a boost from headlines calling Lilly a potential bull-market leader and suggesting the stock could approach $1,100 if momentum continues. Article: Is Eli Lilly Going To $1,100?
• Neutral Sentiment: Lilly and UNICEF announced a $50 million partnership tied to the company’s 150th anniversary, which may help its ESG profile and public image, but the direct earnings impact appears limited in the near term.
• Neutral Sentiment: Some articles were mainly awareness pieces or broad market commentary rather than company-specific catalysts, so they are unlikely to be major stock drivers on their own.
• Negative Sentiment: Broader market commentary warned that the S&P 500 may be due for a correction, which could create short-term pressure on high-multiple growth stocks like Lilly if risk appetite fades.

Eli Lilly and Company Trading Down 0.1%

NYSE LLY opened at $1,005.20 on Friday. The firm has a 50 day simple moving average of $939.88 and a 200-day simple moving average of $997.00. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The firm has a market cap of $946.63 billion, a price-to-earnings ratio of 35.71, a PEG ratio of 1.09 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the firm posted $3.34 earnings per share. The business's revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 2nd. TD Cowen increased their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Thursday, January 29th. Leerink Partners lowered their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating for the company in a research note on Monday, April 27th. UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Finally, Argus increased their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $1,218.33.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.